A long‐term study of flurbiprofen sustained‐release

Abstract

One hundred and twenty patients with arthritis entered a long-term open study of flurbiprofen sustained-rele ase and were assessed at intervals up to 48 weeks. Thirty-seven patients completed 48 weeks, 61 completed at least 24 weeks and 105 at least four weeks of treatment.On the investigator's assessment at 24 weeks, 36 (59 per cent) of 61 patients improved or became well, whilst at 48 weeks, 23 (62 per cent) of 37 patients fell into this category. The median change for quantitative measures of efficacy showed an improvement from that at baseline.Sixty-nine patients (58 per cent) experienced adverse events during the study. Of these, 46 patients (38 per cent) experienced gastrointestinal events. Thirty-three patients withdrew from the study due to adverse events. A fall in mean haemoglobin of 0.6 g/dl occurred over 48 weeks, but the incidence of positive faecal occult blood tests was low and negative results were obtained in most cases, even when haemoglobin levels had fallen.It was concluded that the sustained-rele ase formulation appears to be tolerated satisfactorily over a long time period. It has the advantage of once a day therapy.

Flurbiprofen sustained‐release in OA knee

“…The present study was designed to examine the efficacy and tolerability of the sustained‐release formulation in the treatment of osteoarthritis of the knee. Results of long‐term treatment are described in the third paper 2 and demonstrate that the sustained‐release formulation appeared to be satisfactorily tolerated over a long time period.…”

A general practice study of flurbiprofen sustained‐release

“…The present investigation was designed to examine efficacy and tolerability in comparison with the standard marketed formulation in a short study in general practice. The second paper describes a study in patients with OA of the knee 3 , whilst results of long‐term treatment are described in the third paper 4 .…”